Table 1.
Characterization of EPIC and UKB study participants included in the analyses of blood pressure in relation to risk of renal cell carcinoma
| EPIC |
UKB |
Overall |
|||||
|---|---|---|---|---|---|---|---|
| (PYears: 3 966 871) |
(PYears: 4 739 438) |
(PYears: 8 706 309) |
|||||
| RCC cases | All participants | RCC cases | All participants | RCC cases | All participants | ||
| Overall | 715 | 278 309 | 977 | 422 718 | 1692 | 701 027 | |
| Sex | Female | 320 (44.8%) | 176 812 (63.5%) | 346 (35.4%) | 226 972 (53.7%) | 666 (39.4%) | 403 784 (57.6%) |
| Male | 395 (55.2%) | 101 497 (36.5%) | 631 (64.6%) | 195 746 (46.3%) | 1026 (60.6%) | 297 243 (42.4%) | |
| Age at blood pressure measurement (years) | Median (IQR) | 57.2 (9.8) | 53.3 (12.1) | 61.4 (8.9) | 57.6 (13.3) | 60.1 (9.8) | 55.7 (12.9) |
| BMI (kg/m2) | Median (IQR) | 26.1 (5.0) | 25.0 (5.1) | 28.4 (6.3) | 26.7 (5.7) | 27.5 (5.9) | 26.0 (5.6) |
| Diastolic blood pressure (mmHg) | Median (IQR) | 84.0 (14.0) | 80.0 (14.0) | 83.5 (13.5) | 81.5 (13.5) | 84.0 (13.5) | 81.0 (13.5) |
| Systolic blood pressure (mmHg) | Median (IQR) | 139.0 (25.0) | 130.0 (24.0) | 141.5 (24.0) | 135.5 (24.5) | 140.0 (25.0) | 133.0 (25.5) |
| Smoking status | Current | 213 (30.1%) | 68 376 (24.9%) | 146 (15.0%) | 45 083 (10.7%) | 359 (21.4%) | 113 459 (16.3%) |
| Former | 218 (30.8%) | 80 934 (29.5%) | 406 (41.7%) | 143 311 (34.1%) | 624 (37.1%) | 224 245 (32.3%) | |
| Never | 277 (39.1%) | 124 872 (45.5%) | 421 (43.3%) | 232 199 (55.2%) | 698 (41.5%) | 357 071 (51.4%) | |
| Hypertension treatment | No | 117 (45.7%) | 43 864 (58.6%) | 578 (59.9%) | 335 075 (80.0%) | 695 (56.9%) | 378 939 (76.7%) |
| Yes | 139 (54.3%) | 30 966 (41.4%) | 387 (40.1%) | 83 940 (20.0%) | 526 (43.1%) | 114 906 (23.3%) | |
| Alcohol (g/week) | Median (IQR) | 67.4 (120.5) | 55.8 (97.5) | 156.8 (179.1) | 151.6 (176.6) | 116.4 (155.2) | 111.1 (159.9) |
| Age at diagnosis (years) | Median (IQR) | 66.2 (10.0) | 66.9 (8.9) | 66.7 (9.2) | |||
| Follow-up time to diagnosis (years) | 0–2 | 80 (11.2%) | 146 (14.9%) | 226 (13.4%) | |||
| 2–5 | 93 (13.0%) | 262 (26.8%) | 355 (21.0%) | ||||
| 5–10 | 228 (31.9%) | 484 (49.5%) | 712 (42.1%) | ||||
| >10 | 314 (43.9%) | 85 (8.7%) | 399 (23.6%) | ||||
RCC, renal cell carcinoma; EPIC, European Prospective Investigation into Cancer and Nutrition; UKB, UK Biobank; IQR, interquartile range; PYears, person-years.